Get started

Biotech

$VXRT entry PT 7-8 PT Target PTs 14-17-22Trend-base Fib Extension... Why Vaxart Stock Is Surging Today Investors are excited about the company's experimental COVID-19 vaccine. What happened Shares of Vaxart (NASDAQ:VXRT) climbed on Tuesday after the biotech released promising data from a clinical trial of its oral coronavirus vaccine candidate. As of 3:30 p.m. EDT, Vaxart's stock price was up more than 12%. So what A phase 1 study showed Vaxart's vaccine to potentially be protective against COVID-19, as well as a broad array of other coronavirus-induced illnesses, such as SARS, MERS, and the common cold. "Our vaccine's immune response appears very different than that seen from the leading injectables: mucosal antibodies rather than serum antibodies, and more potent T-cell responses," Vaxart CEO Andrei Floroiu said in a press release. T-cells are a type of white blood cells that can seek out and kill virus-infected cells. They are a vital part of the body's ability to generate an adaptive immune response to specific pathogens. Vaxart's drug produced a stronger T-cell response than Pfizer and Moderna's injectable vaccines, according to Vaxart's chief scientific officer, Dr. Sean Tucker. Now what Should Vaxart's vaccine candidate prove to be safe and effective in later-stage clinical trials, it could become a welcomed new tool in the battle against COVID-19. In such a scenario, the drug would also provide Vaxart with a powerful new revenue and profit driver. Joe Tenebruso (TMFGuardian)
NASDAQ:VXRT
by UnknownUnicorn19246015
ZOM hits lows and bounces back hardI will admit if a trade doesn't come to what I think it will do I'll say im wrong, but that's the beauty of tradingview and how we can share ideas. I still remain skeptical of the current price action and have give a range of price movement of the current price. As a trader watching on the sidelines I still believe for a new/long term trade is wait till earnings. This movement up is unknown why its pumping but a few reasons may be the cause Why is this pumping? -Whole market is recovering at this time and biotech/pennystocks are feeling some love which were one of the worst hit sectors. -Past buyers bought the dip and has had an amazing bounce back, which I will talk about in the TA portion. -The sentiment around ZOM was negative people panic sold from $1.15 too .73, which caused the sellers to be exhausted. With no more sellers the price rebounded and fomo struck. TA: Its interesting cause the chart goes aganist the news, so an idea of this is a short squeeze to exit positions. Who knows -April 22, we skyrocketed towards the 50ema and held causing a bullish reversal in the RSI as it held -RSI leads bullish with the current movement of the stock -Resistance is at 1.41, but could say its at 1.18 with past high or go off the emas, which is at 1.13 and 1.29 -Support would be at the 50 ema .97/.96 or slightly before at 1.01 which could be a dip opportunity. -If the trade goes south you could experience a 29%-74% lost with an upside of 124% going back to ath Final thoughts I'll remain skeptical of this pump till er, since again it could be a pump to have people fomo and sell into the buyers or just exhaustion from the months of downward movement. With TA however it remains bullish/neutral
AMEX:ZOM
by nathanielx9
$BCTX PT 4-4.50BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
NASDAQ:BCTXLong
by UnknownUnicorn19246015
$AGSO Massive Subsidiaries And Upcoming Catalysts. PT - $10+MASSIVE DD Packet Compilation created today of upcoming events and catalysts: t.co NRG currently has 20+ trucks operating in 9 states across the Mid south and Western states. NRG Dynamics is a modern fleet coupled with forward thinking when it comes to technology and operations. They operate completely cloud-based. Considered a specialized carrier with primary focus on MC-331 Tanker, Hauling Liquid Petroleum Gases with Access Agreements or almost every loading facility in the West. During the summer months, part of the fleet is converted to run liquid asphalt (hot oil) and emulsions for road construction. ABOUT US (titannrg.com) NRG RAIL: - RailYard officially turned over for use to NRG Rail from Union Pacific Nov. 20’ The company will be transloading (pictured above) until they begin Phase 1 of the terminal construction which has already been permitted. The Rail yard is composed of 18 rail spots currently and will also feature 9 dual sided towers holding 1.2M gallons of LNG storage on site. - Phase 1 begins with 5 towers, 360k gallons of storage, and two loading racks installed in '21. At that time, the transloader will be retired and the operation will commence operating as a Liquefied Petroleum Gas terminal in Tucson, Arizona. Ape Fuels: - Retail propane provider serving southern Arizona since 2001 by new board of directors member Ginger Cunningham. 1500 leased tanks, 2000+ customers and additional service trucks. Vespene LLC : - Originated in 2011, Vespene LLC provides Titan NRG Partners with wholesale products. It purchases products from the refineries and other various suppliers in the area. You can find the rest of the massive DD in the link provided!!! PT $10+
ALong
by StockGuild
MRNA & end of the bulls?MRNA has had a few wild weeks going up from $120 to $170. I believe this could be the end of the bullishness and it may do a correction. Why do I believe this could happen? MRNA hit historic resistance of $170, after hitting that mark it began dropping. This resistance seems like it can hold. RSI is bounced off the 70 mark on the daily chart. RSI is overbought on the 4HR chart EMA's are beginning to cross over on the hour charts. This could be a tiny correction and just bounce off $160 before continuing its path to $200 so I would keep a close eye on the stock. What I am looking for right now is: 1st support - $160 2nd support - $139_$145 3rd support - $120 At this point MRNA going back down to $100 or even lower seems incredibly unlikely. Moderna's earnings arent too far away so that could act as a catalyzer that will continue the growth. In short I believe that MRNA could have hit the resistance and it will either go down to the listed supports or if it stays in these levels then it will most likely stay like this till earnings come which will tell what direction it is going to go from here. Please comment down your ideas and thoughts on this, I would appreciate any criticism you may have on the charts and analysis, and looking forward to your comments! I am not a financial advisor, these are my personal ideas an thoughts please do your own research before buying a stock.
NASDAQ:MRNAShort
by Geckie
10
Catalent Is about to beat earnings?Now I've been watching Catalent, since they partnered up with one of the stocks I hold for a COVID treatment. Novan. Doing a quick glance at CTLT I noticed a TA pattern known as a double bottom and with certain catalyst coming out, maybe its about to run up and leave this bearish trend. News -ER is in 14 days -They have partnered up with Novan to design the injection of Novan's product that can treat/reduce spread of COVID by 90%, which comes out in Q3. TA As you can see the curve lines represents the two bottoms and the top with two white lines pointing at support points. Now note that this could be just a trading zone, yet we will get into the bullish argument. -MACD a cross over is turning bullish -RSI is rising, yet would need to break 52.47. Also if you want, you could say its already bullish on the RSI with a small error margin in TA. -Resistance would be at 110.87, 114.67, and finally the high of 125-127 -Support is at 106.89 and 100.52. -The emas aren't bad with it ending on top of the 50ema which leans bullish in the short term. -VPVR levels are really high at where it closes today with the resistance in the VPVR at 113 and the support at 106-107 Final thoughts It leans bullish if the Double Bottom pattarn plays out and could see it run up nicely on ER. This ER is Q2 for Catalant, so the COVID play will come out sometime after.
NYSE:CTLTLong
by nathanielx9
NOVAN a biotech stock that might fly very soonDisclaimer: I do own a position and you may want to do your own DD, since this post maybe bias even if its not. Please do your own research. Novan is a pennystock biotech that picked up steam last fall like many pennystocks, but through out 2021 stocks have been getting hit with biotech and pennystocks/low caps being the worst hit sectors. Cathie Woods states in her investment strategy is buy sectors that are hurt the most and that have the protentional to move higher. Novan is its own patient product of nitric oxide throughout United States and Europe and wants to expand on it. News -March 29th The CEO bought 70,000 shares, which is bullish when the CEO is buying -Voting has started and results come in on May 4th. There are many things in here such as increasing the share count by 15million, which shares off 200million doesn't seem much. This doesn't mean shares will get dumped it just means they have the option to do offerings in the future. -Q2 (current quater that last till the end of May possibly June) they will get the results of sb206 B, which looks positive. sb206 will the first every treatment for a skin condition called Mollescum. In doing a quick google search, business wire estimates in 2017 there was over 12million cases and half was in the United States. Googling Mollescum cases in the United States go up 200k a year. Now how does Novan fit into this? Well they would be the only FDA treatment on the market, which would send market shares shoring to a billion dollar valution in a short period time (pt would be around $7). -They also partnered up with Catalent to develop a COVID treatment, which has shown with Novan's product that can reduce the spread of Covid of around 90%. Which catalyst would send Novan to a 10billion dollar valuation, but its up to Catalent. This product is suppose to hit in Q3/Q4, but leans more of a Q3. Pipeline -Like ZOM, Novan is also entering the pet care field, but not a device to do testing. On the last webinar investor prestation, they are working to test their product to help skin dieses in dogs and atm are targeting K9s. This would pickup after sb206 and would get more news sometime around q4 or early next year (most likely when they get the marketing of sb206 going). TA: Now that was alot of "shilling," but its great to know the protentional of a mid/long term play of Novan. It begs the question is if the pennystock is under the radar. Zack Investments and a big advocate in Novan and gave Novan a pt of $4, but 2021 hit and crashed the market. So heres some TA that might help you keep your risk at check if you enter. -Resistance in the short term is at $1.08, but closing was $1.10 on April 16, so $1.13 would act more of a challenge. After that is $1.32, $1.45, and then $1.63. With tight consolidation in the past between $1.63-$1.76, breaking that could shoot up to $1.96 or $2+ -Support: support is tricky cause we are free falling like most pennystocks such as ZOM. I would say a micro 5min scale, Every $0.02 is support, but on the hourly we could fall as low $0.96, but its unlikely. Last year we gain compliance of the $1, so there's a lot of buyers from here too $0.96 that will keep it above $1. Now if we get a negative catalyst we could drop too $0.86-$0.81 -MACD leans bearish as we look for a reversal -RSI is oversold and leans bullish for a bounce back with resistance at 46.89. If people wondering where I get these RSI lines, I look at where its uptrending and make a guess where it breaks and the price starts dropping and the RSI goes from overbought to oversold levels. -VPVR means shit like ZOM's TA, but in the past a lot of support at these levels in the past. -Current EMA 50 is at $1.27, 128 is at $1.40, and the 200 is at $1.45. Final Thoughts Biotechs are risky, but with the CEO buying at $1.40 and seeing the price way below that is a sign to toss in some money or go all in. Its up too you, but I would take the bet and wait this storm out. The confidence between ZOM and Novan is I would pick a stock that has a bigger upside in a near term timeline. Again its best too do your own your research.
NLong
by nathanielx9
3
Biotech Double Bottom (+ Divergence & Bollinger Reversal)Technical Analysis 1. As you see in the chart, we have tested the 200ema 3 times in the past; and it has not trade below it since April 2020. We have made a spinning-bottom on a downtrend, coincidental with a 4th test of the 200ema. 2. RSI and OBV show a positive divergence as the bottom from 2 weeks ago (Test #3) was at a lower level. 3. Bollinger Bands give us another bullish signal, as the first low (Test #3) was outside the lower BB, and the second low (Test #4) was inside the lower BB. Trade Setup A break below Test #3 which is $142.47 could be a potentially good place to set a stop-loss exit. Short-term target to the upside --> $160.5 Mid-term target to the upside --> $170 Trade with care
NASDAQ:IBBLong
by dorfmanmaster
IFRX Technical Analysis 🧙InflaRx NV is a clinical-stage biopharmaceutical company that is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:IFRXLong
by unfair_advantage
Don't fomo into MRNA...yetMRNA made a huge leap on Friday going front $133 to $144. I believe MRNA will resume bullishnes as long as the market remains stable and bullish BUT, MRNA could drop to around $135 before continuing to go up. It still has a way to go on the RSI indicator and EMA's still haven't passed over. If MRNA exists the channel be ready for more mooning to come. Disclaimer: I am not a financial advisor and this is purely my opinion and thought about this stock, do your own research before going into MRNA.
NASDAQ:MRNA
by Geckie
4
No News Pop For CYCNNo news on April 9th and no filings either. But CYCN jumped to $3.10 after-hours. The initial pop began during the final hours of the afternoon session with a big volume spike that pushed the stock back above $3 for the first time, to the upside, in a few weeks. A MELAS Phase 2a study is underway. So the market could be waiting for any updated data to shed light on progress. As it stands right now, top-line data is expected in “mid-2021.” There’s also a Phase 2a study on patients who have Alzheimer’s disease with vascular pathology. The company is expected to initiate this in “mid-2021” as well. Does Friday’s aftermarket momentum have anything to do with its current pipeline? We’ll have to see how Monday begins. In the meantime, CYCN could be one of the penny stocks to watch this week. Quote Source: Best Penny Stocks To Buy Right Now? 3 For This Week’s Watch List
NASDAQ:CYCN
by PennyStocks101
CFRX a great risks/reward ratio! 🧙ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
CLong
by unfair_advantage
1
AQB is on the watchlistAquaBounty (AQB) NASDAQ:AQB AquaBounty is a company that deals currently in aquaculture services, specializing in the farming of bioengineered Atlantic salmon that can grow to market size faster than what the conventional market offers. The appeal in ABQ is clear. As global natural salmon production decreases due to environmental constraints put upon by climate change and pollution, aquaculture of salmonids is already used to meet market demands at a competitive price. Bioengineered salmon is reportedly faster to produce and more efficient; therefore, following conventional logic, bioengineering salmon is the logical next step for a competitive market to meet increasing demands. Their product is known as the: Aquadvantage Salmon Cathie Wood from ARK invest has backed this and they currently own 12.18%/ 8,640,421 shares. The Vanguard Group also have a stake of 2.09% with Blackrock trailing behind at 0.82% My only concern is the public perception of GMO foods. As reported by The Hartman Group, consumer perception of GMO foods is increasingly negative year by year. Chains such as Costco have refused to serve these GMO salmons which may pose a potential risk for ABQ in the short term. But long term we will have to continue modifying organisms in order to reach a point of sustainability. Looking at the chart we could retest 10$ again easily before Earnings. Due to the fact, their patented product hasn't yet arrived in the US, it could crash back after if it doesn't beat estimate EPS. Then again, it is FDA approved so hopefully, it will take the market by storm when things open up again in the summer. If it drops to the 5$ range I will open a long position. If it consolidates at 7-8$ I may reconsider. (Disclaimer not financial advice just opinion)
NASDAQ:AQBLong
by jackohgorman
BIIB has incoming Golden Cross, rising past support zone?Hi. In this 1D chart I've marked an impending Golden Cross: the point where a MA 56 is very likely to cross a MA 224 upwards. With this I've also plotted out a Resistance zone and a Support zone. The price has just entered the Resistance zone but instead of turning back this time the momentum of the Golden Cross should push it past the Resistance zone. I've also included two example trades. One has its SL placed on the price of the Golden Cross and then given a ratio of two to make a reasonable TP. The other has its SL placed on the top line of the Support zone and given a ratio of 1.75 to make a more conservative long position and keep the TP within a reasonable price. Thank you. Please, if you have any thoughts or comments do leave them below and I would gladly discuss or adjust my interpretations and methods with you. This does not constitute financial advice. Any projected prices, even if explicitly stated, are made with intent to discuss the symbol and potential interpretations. Any trades shown or mentioned are examples and neither recommendations or mandates.
NASDAQ:BIIBLong
by Kabeldon
BNGO round 2!!!!This play looks tempting ngl. NASDAQ:BNGO Bionanon made very tasty returns so why not return. Price is near 0+/- ATR in keltner and if it closes above I will enter. Last time I entered around $5 and avg'ED up till $5.6. Took Profit around $14 but this chart looks promising. Genomics is still an underrated sector and there are many supporters of its hot product -' The Saphyre system' Let's see how this runs. Good luck Entry - $7-$8 since it bottomed at $6.90. Set trailing SL of 15%. TP - $9-$10, since it might test resistance and bounce back down. Great company but burns through cash, so some major hyped event would need to occur for it to retest ATH. (Disclaimer this is not financial advice just my opinion)
NASDAQ:BNGOLong
by jackohgorman
1